Continuous monitoring after second-generation cryoballoon ablation for paroxysmal atrial fibrillation in patients with cardiac implantable electronic devices.


Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
02 2019
Historique:
received: 19 03 2018
pubmed: 21 8 2018
medline: 3 10 2020
entrez: 21 8 2018
Statut: ppublish

Résumé

The second-generation cryoballoon (CB) is effective in achieving pulmonary vein isolation. Continuous monitoring would eliminate any over- or underestimated freedom from atrial fibrillation (AF) postablation. The purpose of this study was to differentiate between arrhythmias occurring after cryoballoon ablation (CBA), detecting true AF in symptomatic patients and detecting silent subclinical AF. Between June 2012 and January 2015, 54 patients with a preexisting cardiac implantable electronic device (CIED) who had undergone CBA for paroxysmal atrial fibrillation (PAF) were included in our retrospective study. Regular CIED controls, physical examination, and ECG recordings were performed by an experienced cardiologist blinded to the ablation procedure. Data on any hospitalization during follow-up were gathered. Patients were encouraged to note all clinical symptoms during follow-up. Continuous monitoring showed a success rate of 83.3% after 1 year and 75.93% after 3 years of follow-up. During the first year, 68% of episodes of palpitations after ablation were due to sinus tachycardia, nonsustained ventricular tachycardia, or supraventricular tachycardia. AF recurrence was detected in 15.6% of asymptomatic patients during follow-up. Total AF burden post-CBA had decreased to 0.64% ± 4.34% (P <.001) during long-term follow-up of 3.3 years. Although this is a selected group of patients with a preexisting CIED, continuous monitoring showed freedom from AF in 83.3% of patients post-CBA after 1 year and 75.93% after 3 years of follow-up.

Sections du résumé

BACKGROUND
The second-generation cryoballoon (CB) is effective in achieving pulmonary vein isolation. Continuous monitoring would eliminate any over- or underestimated freedom from atrial fibrillation (AF) postablation.
OBJECTIVE
The purpose of this study was to differentiate between arrhythmias occurring after cryoballoon ablation (CBA), detecting true AF in symptomatic patients and detecting silent subclinical AF.
METHODS
Between June 2012 and January 2015, 54 patients with a preexisting cardiac implantable electronic device (CIED) who had undergone CBA for paroxysmal atrial fibrillation (PAF) were included in our retrospective study. Regular CIED controls, physical examination, and ECG recordings were performed by an experienced cardiologist blinded to the ablation procedure. Data on any hospitalization during follow-up were gathered. Patients were encouraged to note all clinical symptoms during follow-up.
RESULTS
Continuous monitoring showed a success rate of 83.3% after 1 year and 75.93% after 3 years of follow-up. During the first year, 68% of episodes of palpitations after ablation were due to sinus tachycardia, nonsustained ventricular tachycardia, or supraventricular tachycardia. AF recurrence was detected in 15.6% of asymptomatic patients during follow-up. Total AF burden post-CBA had decreased to 0.64% ± 4.34% (P <.001) during long-term follow-up of 3.3 years.
CONCLUSION
Although this is a selected group of patients with a preexisting CIED, continuous monitoring showed freedom from AF in 83.3% of patients post-CBA after 1 year and 75.93% after 3 years of follow-up.

Identifiants

pubmed: 30125716
pii: S1547-5271(18)30815-4
doi: 10.1016/j.hrthm.2018.08.015
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

187-196

Informations de copyright

Copyright © 2018 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Rajin Choudhury (R)

Heart Rhythm Management Center, Postgraduate Course in Clinical EP and Pacing, Vrije Universiteit Brussel, Brussels, Belgium; QE II HSC, Heart Rhythm Service, Division of Cardiology, Halifax, Canada.

Hugo-Enrique Coutino (HE)

Heart Rhythm Management Center, Postgraduate Course in Clinical EP and Pacing, Vrije Universiteit Brussel, Brussels, Belgium.

Radu Darciuc (R)

Medpark International Hospital, Chisinau, Republic of Moldova.

Erwin Ströker (E)

Heart Rhythm Management Center, Postgraduate Course in Clinical EP and Pacing, Vrije Universiteit Brussel, Brussels, Belgium.

Valentina De Regibus (V)

Heart Rhythm Management Center, Postgraduate Course in Clinical EP and Pacing, Vrije Universiteit Brussel, Brussels, Belgium.

Giacomo Mugnai (G)

Heart Rhythm Management Center, Postgraduate Course in Clinical EP and Pacing, Vrije Universiteit Brussel, Brussels, Belgium.

Gaetano Paparella (G)

Heart Rhythm Management Center, Postgraduate Course in Clinical EP and Pacing, Vrije Universiteit Brussel, Brussels, Belgium.

Muryio Terasawa (M)

Heart Rhythm Management Center, Postgraduate Course in Clinical EP and Pacing, Vrije Universiteit Brussel, Brussels, Belgium.

Varnavas Varnavas (V)

Heart Rhythm Management Center, Postgraduate Course in Clinical EP and Pacing, Vrije Universiteit Brussel, Brussels, Belgium.

Francesca Salghetti (F)

Heart Rhythm Management Center, Postgraduate Course in Clinical EP and Pacing, Vrije Universiteit Brussel, Brussels, Belgium.

Saverio Iacopino (S)

Villa Maria Cecilia, Villa Maria Care and Research, Cotignola, Italy.

Ken Takarada (K)

Heart Rhythm Management Center, Postgraduate Course in Clinical EP and Pacing, Vrije Universiteit Brussel, Brussels, Belgium.

Juan-Pablo Abugattas (JP)

Heart Rhythm Management Center, Postgraduate Course in Clinical EP and Pacing, Vrije Universiteit Brussel, Brussels, Belgium.

Juan Sieira (J)

Heart Rhythm Management Center, Postgraduate Course in Clinical EP and Pacing, Vrije Universiteit Brussel, Brussels, Belgium.

Pedro Brugada (P)

Heart Rhythm Management Center, Postgraduate Course in Clinical EP and Pacing, Vrije Universiteit Brussel, Brussels, Belgium.

Carlo de Asmundis (C)

Heart Rhythm Management Center, Postgraduate Course in Clinical EP and Pacing, Vrije Universiteit Brussel, Brussels, Belgium.

Gian-Battista Chierchia (GB)

Heart Rhythm Management Center, Postgraduate Course in Clinical EP and Pacing, Vrije Universiteit Brussel, Brussels, Belgium. Electronic address: gbchier@yahoo.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH